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ABSTRACT
Alterations in the activity of the centrosomal kinase,
Aurora-A/STK15, have been implicated in centro-
some ampli®cation, genome instability and cellular
transformation. How STK15 participates in all of
these processes remains largely mysterious. The
activity of STK15 is regulated by phosphorylation
and ubiquitin-mediated degradation, and physically
interacts with protein phosphatase 1 (PP1) and
CDC20. However, the precise roles of these
modi®cations and interactions have yet to be fully
appreciated. Here we show that STK15 associates
with a putative tumor and metastasis suppressor,
NM23-H1. STK15 and NM23 were initially found to
interact in yeast in a two-hybrid assay. Association
of these proteins in human cells was con®rmed by
co-immunoprecipitation from cell lysates and bio-
chemical fractionation indicating that STK15 and
NM23-H1 are present in a stable, physical complex.
Notably, SKT15 and NM23 both localize to centro-
somes throughout the cell cycle irrespective of the
integrity of the microtubule network in normal
human ®broblasts.
INTRODUCTION
Correct partitioning of the genome during mitosis depends
upon the tightly regulated function of the mitotic spindle,
which is composed of centrosomes, microtubules, molecular
motors, chromosomes and kinetochores. The centrosome is
the major microtubule-organizing center in mammalian cells
and the counterpart to the spindle pole body of the yeast
Saccharomyces cerevisiae. The centrosome in mammalian
cells is composed of two perpendicularly positioned centrioles
and the surrounding amorphous pericentriolar material.
g-Tubulin and pericentrins are constitutive components of
the centrosome, while other proteins, such as p53, pRB,
BRCA1, BRCA2 and CDK2, accumulate at centrosomes in a
cell cycle-dependent manner (1±4).
The centrosome normally duplicates once per cell cycle.
This process is initiated during G1 after cells pass the
restriction point and is completed during G2. Centrosomes
separate at G2/M, migrating to opposite poles of the cell to
establish the microtubule network that is required to separate
condensed chromosomes during M phase. Centrosomes play a
vital role in establishing spindle bipolarity, in assembling
spindle microtubules and in determining the plane of
cytokinesis (for reviews see 5±10). More recently, accumu-
lating evidence suggests a more direct role than had previously
been appreciated for the centrosome in cytokinesis and cell
cycle progression during the following G1 and S phases
(11±13).
Centrosome abnormalities, including morphological
alterations, supernumerary centrosomes and acentriolar
centrosomes, have been demonstrated in most human cancer
cells, including those derived from breast, prostate, lung,
colon and brain (for reviews see 14,15; see also 2,16±18).
Several oncogenes, tumor suppressor genes, cell division
cycle and mitotic checkpoint genes are required for or
involved in centrosome duplication, such as Ras, BRCA1
and BRCA2, CDK2, cyclin A and ATR (3,19±23). Like other
cellular processes, protein kinases play critical roles in the
centrosome duplication process. Among the centrosome-
associated kinases, Aurora-A/AIK1/BTAK/STK15 kinase
has been identi®ed as a candidate oncogene with connections
to the centrosome cycle (24±27). Aurora-A/STK15 is over-
expressed at both the mRNA and protein levels in a number of
cancer cell lines, including breast, ovarian and prostate
(25,27), and also in breast cancer tissues (28±30). Its kinase
activity peaks at the G2/M phase of the cell cycle (25). A
mutant, kinase-inactive STK15 (Stk15 K162M) abolishes the
oncogenic activity of STK15 in Rat1 ®broblasts, while a
mutation conferring constitutive activation (Stk15 T288D)
increases the kinase activity and enhances transforming
potential (25). These results strongly suggest that the kinase
activity of STK15 is essential for STK15 function in vivo.
STK15 is regulated by phosphorylation and ubiquitin-medi-
ated degradation and interacts with CDC20 and protein
phosphatase 1 (PP1) (31±35).
As a putative tumor suppressor, the nm23 gene was
discovered on the basis of its reduced expression in highly
metastatic cell lines (36). Several studies have shown that
NM23 overexpression can reduce the metastatic potential of
melanoma and breast carcinoma cells in vivo (37±39).
Furthermore, nm23 expression, at both the protein and
mRNA levels, inversely correlates with high metastatic
potential in numerous human cancers, including breast,
gastric, cervical and ovarian carcinoma and melanoma (for a
review see 40).
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The nm23 genes encode a protein family with eight
subfamilies in human (41). The well characterized bio-
chemical activities of these proteins include NDP kinase
(42), protein histidine kinase, histidine-dependent protein
phosphotransferase (43±45) and serine autophosphorylation
(46,47). Data suggest that it is the level of autophosphoryla-
tion that correlates with tumor suppression by NM23 in
melanoma cells (46). NM23 associates with the cytoskeleton
through an interaction with b-tubulin (48). Awd, the ¯y
homolog of NM23, co-localizes with microtubules in
Drosophila cells (49) and more recent data have indicated
that NM23 may also be a component of the centrosome (50).
Despite the strong evidence that STK15/Aurora-A/BTAK
regulates centrosome duplication, cellular transformation and
aneuploidy, little evidence directly connects this kinase with
known oncogenes or tumor suppressors. Here we provide the
data that STK15 interacts with the tumor suppressor NM23,
both in yeast and in normal human ®broblasts. NM23 and
STK15 co-fractionate in a high molecular weight complex and
co-localize at centrosomes throughout the cell cycle.
MATERIALS AND METHODS
Plasmids and primers
Full-length STK15 was obtained by PCR from plasmid
pcDNA3-STK15/BTAK (a kind gift from Dr S. Sen; 27)
using the primers STK15-CHIS5 (CGGGATCCCGG-
GGATGGACCGATCTAAAGAAACTGC) and STK15-
3XhoI (CCGCTCGAGCTAAGACTGTTTGCTAGCTGA-
TTC). STK15-GBT8 was constructed by cloning into the
BamHI and XhoI sites of pGBT8. A HeLa cDNA two-hybrid
library was used in the two-hybrid screen (51). Full-length
nm23-H1 cDNA was obtained by PCR of EST clones ordered
from Genome Systems Inc. (EST clones 590228 and 3454119)
using the primers NM23GAD-5EcoRI (CGGAATTCCA-
TGGCCAACTGTGA-GCG) and NM23-3XhoI (CCGCTC-
GAGTCATTCATAGATCCAG). pGADGH-NM23-H1 was
constructed by cloning the the PCR product into the EcoRI and
XhoI sites of pGADGH (51).
Cell culture
Human IMR90 cells were purchased from ATCC (CCL-186).
These were immortalized by infection with a hTERT retro-
virus at passage 25 (52). The cells were cultured at 37°C in a
5% CO2 incubator in Dulbecco's modi®ed medium (DMEM)
supplemented with 10% (v/v) heat-inactivated fetal bovine
serum (FBS), 10% (v/v) non-essential amino acids (NEAA)
and penicillin/streptomycin (100 IU/ml and 100 mg/ml,
respectively). Nocodazole treatment was done by addition of
10 mg/ml nocodazole to the culture medium followed by
incubation for 10 min at 37°C.
Two-hybrid screening
To identify proteins interacting with STK15, we screened a
plasmid library of fusions between the GAL4 activation
domain (GAD, residues 768±881) and HeLa cell cDNA
fragments. The Gal4 DNA-binding domain (GBD) is fused
with STK15 in the pSTK15-GBT8 construct. The screen was
done in a S.cerevisiae reporter strain (pJ64-4a, W303MATa
trp9-901, 112 ura3-52 his3-200 gal4 gal80 GAL2-ADE2
LYS2::GAL1-HIS3 met2::GAL7-LacZ, a kind gift from
R. Rothstein). A total of 1.2 3 106 transformants were
assayed on synthetic drop-out medium (without leucine,
histidine and tryptophan, SC ±HLW) plates. A total of 104
colonies turned blue on X-gal plates, and the plasmids were
recovered from 54 colonies. Retransformation of the plasmids
into the test strain con®rmed that 20 plasmids retained the
ability to activate the b-galactosidase reporter. Sequencing
analysis revealed four plasmids contained coding sequences
from nm23-H1 genes. The four plasmids were derived from
two independent cDNAs comprising nucleotides 25±330 and
4±159 of the nm23-H1 coding region.
Antibodies
A polyclonal antiserum against STK15 (anti-STK15) was
raised in rabbits by presenting a KLH-conjugated nine amino
acid peptide (synthesized by Research Genetics, Huntsville,
AL) from the C-terminus of STK15 (NKESASKQS). The
serum was af®nity puri®ed using a resin prepared from the
synthesized peptide (53). The antibody recognizes a 46 kDa
band in whole cell lysates. For some studies, the af®nity-
puri®ed antibody was labeled with Alexa Fluor 647 dye
(Molecular Probes, Eugene, OR), for example for examination
of cells triple labeled by anti-b-tubulin-FITC, anti-NM23-H1-
TRITC and anti-STK15-AF647 antibodies. Af®nity-puri®ed
anti-NM23 antibodies were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA) (rabbit polyclonal sc-343
and sc-343-TRITC for immuno¯uorescence and mouse
monoclonal sc-465 for immunoprecipitation). Mouse mono-
clonal anti-centrin2 antibody was a kind gift from Dr J. L.
Salisbury (Mayo Clinic, Rochester, MN). Monoclonal anti-g-
tubulin (T-3195) and FITC-conjugated mouse monoclonal
anti-b-tubulin were obtained from Sigma (St Louis, MO).
Secondary antibodies were obtained from Pierce (Rockford,
IL), Jackson Immunoresearch Laboratory Inc. (West Grove,
PA) and Molecular Probes Inc. (Eugene, OR).
Immunoblotting, immunoprecipitation and ¯uorescence
microscopy
IMR90 cells were lysed in IP buffer [125 mM NaCl, 1 mM
Mg(OAc)2, 1 mM CaCl2, 5 mM EGTA, 20 mM HEPES
(pH 7.6), 1% (v/v) NP-40, with freshly dissolved 2 mM DTT,
0.2 mM phenylmethylsulfonyl ¯uoride and protease inhibitors
(Roche, Mannheim, Germany)] on ice for 10±15 min. Protein
concentrations were determined by Bradford assay (Bio-Rad).
A total of 10±50 mg protein was analyzed by 10 or 12% (v/v)
SDS±PAGE (54).
Immunoprecipitation was performed as described (55) with
the following modi®cations. IMR90 cells were lysed in IP
buffer at 4°C for 10 min. The cell lysate was cleared by
centrifugation at 10 000 g for 10 min at 4°C. The supernatant
was pre-cleared by incubation for 30 min with
agarose±protein A or agarose±protein G beads (Pierce). The
supernatant was further incubated with 5 mg antibodies for
3±4 h at 4°C with agitation, after which agarose±protein A or
A/G mixture (pre-blocked by incubation with 5% BSA) was
added for 1 h at 4°C. The beads were then washed three times
with IP buffer. For release of STK15 and associated proteins,
beads were incubated with 1 mg/ml synthetic antigen in
phosphate-buffered saline (PBS) for 1 h at 4°C with agitation.
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For indirect immuno¯uorescence, cells were grown on acid-
washed 13 mm square glass coverslips (Fisher Scienti®c,
Pittsburgh, PA). Cells were ®rst ®xed with 0.5% (w/v)
formaldehyde in PBS (pH 7.2) for 15 min at room temperature
and then washed four times with PBS. Fixed cells were
permeabilized by 0.1% (v/v) Triton X-100 in PBS with 1%
(v/v) normal goat serum (NGS) and then washed with PBS
with 1% (v/v) NGS (Gibco-BRL). The primary antibodies
used were anti-STK15 1:100, anti-NM23 1:200, anti-centrin2
1:200 and anti-b-tubulin-FITC 1:25, at room temperature for
1 h. Secondary antibodies were diluted in the blocking buffer
at 1:100 or 1:200 and incubated for 1 h at room temperature in
the dark. The ®rst wash after secondary antibody included
1 mg/ml Hoechst 33342 (Sigma) for 15 min at room
temperature. For triple labeling, the primary antibodies used
were as follows: anti-b-tubulin-FITC 1:25, anti-NM23-TRITC
1:50 and anti-STK15-AF647 1:50. Coverslips were mounted
on glass slides with mounting medium. Microscopy was
carried out on Nikon or Zeiss microscopes with 633 or 1003
oil immersion lens. The images were captured with Openlab
(Lexington, MA) software and saved as TIFF ®les.
Biochemical fractionation of STK15 and NM23
For fractionation of STK15 and NM23, IMR90 cells were
lysed as above and the lysates were cleared by centrifugation
at 10 000 g for 10 min at 4°C. The supernatants were cleared
by passage through a 0.2 mm ®lter and fractionated through
three chromatographic steps, Mono S, Mono Q and Superose 6
HR10/30 (Amersham-Pharmacia Biotech, Piscataway, NJ), in
an AKAT FPLC system. The cell lysates were loaded ®rst on
Mono S and eluted with a linear gradient of from 100 to
1000 mM potassium chloride in MonoS buffer [20 mM
HEPES (pH 7.6), 10% (v/v) glycerol, 1 mM DTT, 1 mM
EDTA, 0.01% (v/v) NP40]. Fractions were collected (0.5 ml)
and those containing the peak of STK15 1.5 ml (from 280 to
370 mM) were collected and dialyzed against MonoQ buffer
[20 mM HEPES (pH 8.0), 10% (v/v) glycerol, 1 mM DTT,
1 mM EDTA, 0.01% (v/v) NP40, containing 100 mM NaCl].
The dialyzed eluate was then loaded onto Mono Q and was
eluted with a linear gradient from 0 to 1000 mM potassium
chloride in MonoQ buffer. The peak fractions for STK15
(from 350 to 450 mM) were collected and pooled before 0.5 ml
was loaded onto Superose 6. The column was run at 0.4 ml/min
with Super6 buffer [20 mM HEPES (pH 7.6), 10% (v/v)
glycerol, 1 mM DTT, 1 mM EDTA, 0.01% NP40 and 300 mM
NaCl]. Fractions of 1 ml were collected and proteins were
precipitated with TCA. The pellets were then re-dissolved
in 0.1 N NaOH and loaded onto SDS±PAGE gels for
immunoblot analysis.
RESULTS AND DISCUSSION
NM23 and STK15 interact
To search for proteins that interact with STK15 we conducted
a yeast two-hybrid screen using the full-length STK15 coding
sequence as a bait (see Materials and Methods). Among the
positives, we found four plasmids containing the human
nm23-H1 coding sequence. Two different fusions were
represented, which cover a common N-terminal region of
NM23-H1 (three represented fusions of Gal4 to amino acids
9±110, and another represented amino acids 2±53). This
suggests that the region of NM23-H1 between amino acids 2
and 53 binds directly to STK15. We inserted the full-length
nm23-H1 coding sequence into pGADGH (pGADGH-NM23-
H1) and con®rmed that this fusion protein also interacts
speci®cally with STK15 (Fig. 1). Only in combination with
STK15 did colonies carrying NM23-H1 show signi®cant
b-galactosidase expression. Neither NM23-H1 alone nor
NM23 combined with other Gal4 fusion proteins (e.g. ras)
induced b-galactosidase expression. However, at least in
yeast, the degree of X-gal staining indicated that the
interaction between STK15 and Nm-23H1 was relatively
weak, as compared to the positive control (pGBT8-Ras and
pGADGH-Raf in this case). It was therefore essential to
Figure 1. STK15 and NM23 interact speci®cally in the two-hybrid assay.
Transformants of S.cerevisiae strain pJ64-4a were grown and re-patched on
synthetic complete plates lacking Leu and Trp to select for both pGBT and
pGADGH plasmid derivatives. The patches were transferred to Whatman
No. 1 ®lter paper for b-galactosidase assays and the color was developed at
37°C for 1 h. A combination of pGBT8-Ras and pGADGH-Raf served as
the positive control.
Figure 2. STK15 and NM23 co-immunoprecipitate. Protein lysates from im-
mortalized IMR90 cells were cleared by centrifugation and immunoprecipi-
tated with anti-STK15 plus STK15 polypeptide antigen competitor (lane 1),
anti-STK15 alone (lane 2), normal mouse IgG (lane 3) and anti-NM23-H1
(lane 4). The immunoprecipited proteins were fractionated by SDS±PAGE
and transferred to nitrocellulose membrane for western blotting. STK15 and
NM23-H1 are indicated by arrows.
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Figure 3. STK15 and NM23-H1 co-fractionate. Protein lysates from immortalized IMR90 cells were fractionated on Mono S, Mono Q and Superose 6 col-
umns. Fractions 8±25 of 1 ml volume were collected after the ®nal Superose 6 gel ®ltration column and constituent proteins were separated by SDS±PAGE
for western blotting. STK15 and NM23-H1 are indicated by arrows.
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investigate whether these proteins physically interacted in
mammalian cells.
To test whether STK15 and NM23 also interact in vivo in
human cells, proteins were immunoprecipitated from IMR90
cell lysates using anti-STK15 and anti-NM23 antibodies (see
Materials and Methods). The presence of NM23 and STK15 in
the precipitate was examined by western blotting (Fig. 2).
Anti-STK15 speci®cally co-immunoprecipitates STK15 and
NM23. Pre-incubation of the STK15 antibody with its cognate
synthetic antigen coordinately abolished immunoprecipitation
of both STK15 and NM23 (Fig. 2, lanes 1 and 2). The NM23
antiserum also immunoprecipitated NM23 and STK15, while
normal mouse IgG did not bring down signi®cant amounts of
either NM23 or STK15 (Fig. 2, lanes 3 and 4). We did detect
some non-speci®c binding of NM23 to protein A/G beads;
however, this is not unexpected considering that NM23 is a
relatively abundant protein (lane 3). The foregoing results
indicate that STK15 and NM23 associate with each other in
human cells. Comparing the total amount of NM23 present in
the cell and the amount precipitated by anti-NM23-H1
antibody (Fig. 2, lane 4, and western data not shown) to the
amount of NM23 immunoprecipitated by the STK15 antibody
(Fig. 2, lane 2; both lanes 2 and 4 were from the same amount
of cell lysate) suggests that a relatively small percentage of
NM23-H1 exists in a stable, physical complex with STK15. In
western blots of the anti-STK15 immunoprecipitations, we
also detected another protein of ~54 kDa, in addition to the
46 kDa protein that is predicted to be an STK15 protein
derived from an alternatively spliced mRNA. We have not
de®nitively determined the identity of the 54 kDa protein;
however, the human genome sequencing project has predicted
an alternatively spliced STK15 transcript that is predicted to
generate a protein of this size (accession no. XP_009546). In
contrast, we have con®rmed that the ~46 kDa band is STK15
by MALDI-TOF mass spectrometry.
To verify the interaction between STK15 and NM23-H1,
protein extracts from IMR90 cells were fractionated by FPLC.
Throughout the puri®cation, we followed STK15 by western
blotting. Western analysis of the puri®cation through Mono S,
Mono Q and Superose 6 columns revealed that STK15 is
present in two distinct forms, a high molecular weight protein
complex (Fig. 3, fractions 10 and 11, ~2 MDa) and a relatively
low molecular weight complex (fractions 15±17, ~350 KDa).
NM23-H1 also shows a peak around fractions 15±17, which
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exactly co-migrates with STK15 in the ~350 kDa complex
(Fig. 3). This result supports the notion that STK15 and NM23
coexist in a protein complex in vivo.
STK15 and NM23 co-localize at centrosomes
It has been shown that STK15 localizes to centrosomes in
mitotic cells (25) (Fig. 4A). By ®xing IMR90 cells in 0.5%
(w/v) formaldehyde, we can also detect STK15 at centrosomes
during interphase in immortalized human IMR90 cells.
Centrosomes were visualized by simultaneous staining with
an anti-centrin2 antiserum, which locates the two centrioles in
the centrosome (Fig. 4). The amount of STK15 at centrosomes
increases as cells move from interphase to prophase, and
SKT15 also becomes apparent on the mitotic spindle. These
results suggest that STK15 is a centrosome component
throughout the cell cycle (Fig. 4A), but becomes enriched at
centrosomes during mitosis. NM23-H1 also localizes to
centrosomes in interphase cells (Fig. 4B) (50). At the
beginning of prophase NM23-H1 accumulates at the centro-
some, as judged from the increased intensity of staining
(Fig. 4B, prometaphase) (50). The association of NM23 with
centrosomes persists through the mitotic phase and NM23-H1
also distributes somewhat to the microtubule spindles adjacent
to the centrosome from metaphase to telophase (Fig. 4B) (50).
From late telophase to cytokinesis, NM23-H1 also accumu-
lates at the newly forming midbody microtubules (Figs 4C and
5C in late telophase and cytokinesis cells). Interestingly, an
identical distribution pattern at the midbody microtubules is
also observed for STK15 (Figs 4C and 5B in late telophase and
cytokinesis cells). The accumulation of NM23-H1 on centro-
somes coincides with the enrichment of STK15 at the
centrosome and with increased STK15 kinase activity at the
beginning of mitosis (25).
In order to test whether STK15 and NM23 co-localize, we
simultaneously labeled IMR90 cells with b-tubulin-FITC,
NM23-TRITC and STK15-AF647 (Cy5) and visualized the
localization of each protein (Fig. 4C). b-Tubulin immuno-
¯uorescence reveals interphase microtubule ®laments and
centrosomes. In mitotic phase, b-tubulin localizes both to the
mitotic spindles and to the centrosomes (Fig. 4C). NM23 and
Figure 4. (Previous two pages and above) STK15 and NM23-H1 localize to centrosomes throughout the cell cycle. IMR90 cells were plated on glass
coverslips and cultured in growth medium for 24 h before ®xation with paraformaldehyde. The centrosome was visualized with anti-centrin2 and Texas
red-labeled secondary antibodies. (A) STK15 and (B) NM23-H1 were visualized with anti-STK15 and anti-NM23-H1, respectively, and FITC-labeled
secondary antibodies. DNA was labeled by Hoechst 33342 or DAPI staining. The composite images are STK15 or NM23 merged with centrin2 and DAPI.
The green NM23 or STK15 merged with red centrin2 produces yellow spots in the composite image, indicating that NM23 and STK15 localize to the
centrosomes. (C) Cells were labeled with anti-b-tubulin-FITC, anti-NM23-TRITC and anti-STK15-AF647 (Cy5) simultaneously and visualized on the
microscope with FITC, TRITC, Cy5 and DAPI ®lters, respectively. Cell cycle stages are indicated on the left.
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STK15 ¯uorescence is present together at the centrosome at
all cell cycle phases (Fig. 4C, the right side merged lane).
These results con®rm that STK15 and at least some fraction of
NM23 co-localize to centrosomes throughout the cell cycle.
STK15 and NM23 centrosomal localization is
microtubule-independent
There is some evidence indicating that NM23-H1 is b-tubulin
associated and localized through g-tubulin to centrosomes
(48,50). In order to clarify that STK15 and NM23 do not
associate indirectly at centrosomes through their separate
interactions with microtubules, we treated IMR90 cells with
nocodazole (see Materials and Methods), which rapidly
dissipates the microtubule network in cells (Fig. 5B and C,
b-tubulin column).
There are several centrosome-associated proteins that
localize to this structure in a spindle-dependent fashion. Of
these, perhaps the most well studied is g-tubulin (56). Upon
nocodazole treatment of mammalian cells, centrosomal
g-tubulin is reduced by ~2-fold in interphase cells and by at
least 4-fold in mitotic cells (56). Using b- and g-tubulin
antisera, we con®rmed that our nocodazole treatment dissi-
pates the microtubule network and dramatically reduces the
amount of g-tubulin associated with the centrosome
(Fig. 5A±C). In such cells, STK15 and NM23-H1 still localize
to the centrosome with the same pattern and intensity of
staining seen in untreated cells (Fig. 5B and C). The result
suggests that the interaction between STK15 and NM23 and
their centrosome localization are microtubule-independent.
A previous study (57) showed that the centrosomal
localization of a Xenopus laevis homolog of STK15,
Aurora-A, is microtubule-dependent. This result was obtained
using a construct consisting of the only N-terminal domain of
Aurora-A (57). However, microtubule-independent localiza-
tion of Aurora-A to the centrosome was observed using a full-
length Aurora-A construct (57). Here, we also observed that
the localization of full-length STK15 to the centrosome is not
dependent on microtubules (Fig. 5B).
A previous study showed that STK15 associates with
centrosomes only at onset of mitosis (25). However, our
immuno¯uorescence studies indicate that STK15 associates
with centrosomes throughout the cell cycle. This discrepancy
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could arise because of the different cell types used in these
studies. Here we examined STK15 in normal or immortalized
human ®broblasts cells while previous studies have used
human cancer cells and rodent ®broblast cells. Furthermore,
different antisera and ®xation conditions were used in this and
in previous studies. We do, however, observe an increase in
the abundance of STK15 at centrosomes in mitotic cells.
STK15 is a centrosome-associated kinase, overexpression
of which in rodent or human cancer cells causes improper
centrosome duplication, aneuploidy and cellular transform-
ation (25,27). The abundance of STK15 is controlled by the
ubiquitin pathway (32,33) and has been linked to CDC20, an
APC activator (31). STK15 kinase activity is also controlled
by PP1, a protein phosphatase (34). Here we provide evidence
that STK15 is associated with a putative tumor and metastasis
suppressor protein, NM23-H1. These proteins physically
interact and co-localize to centrosomes throughout the cell
cycle in human IMR90 cells. NM23-H1 plays important roles
in cell proliferation, differentiation, tumorigenesis and
metastasis.
The interaction between NM23 and STK15 might poten-
tially modulate either of their activities through a number of
mechanisms, ranging from allosteric regulation to induced
localization to enzymatic modi®cation. We tested the latter
possibility using STK15 and NM23-H1, puri®ed from
Escherichia coli. Puri®ed STK15 was enzymatically active,
as judged by its ability to phosporylate a model substrate,
MBP. NM23 also displayed activity as judged by auto-
phosphorylation and NDP kinase activities (data not shown;
46,58). Neither of the puri®ed proteins was capable of
chemically modifying the other nor did mixing these proteins
affect their activities towards model substrates in vitro.
Therefore, the exact nature of the functional relationship
between NM23 and SKT15 remains unknown.
ACKNOWLEDGEMENTS
We would like to thank J. L. Salisbury (Mayo Clinic,
Rochester, MN) for the kind gift of the anti-centrin2
antiserum, S. Sen (University of Texas M.D. Anderson
Cancer Center, Houston, TX) for the STK15 plasmid,
R. Rothstein (Columbia University) for the yeast two-hybrid
strain pJ64-4a and Y. Seger (Cold Spring Harbor) for the
hTERT retroviral plasmid. The authors would also like to
thank D. Conklin, M. Carmell, S. Hammond, A. Caudy and
other members in the laboratory for technical support and
helpful discussions. We are thankful to Stephen Hearn and
Gayle Lark at the core microscopy facility and Jim Duffy in
5472 Nucleic Acids Research, 2002, Vol. 30, No. 24
 at Cold Spring H
arbor Laboratory on D
ecem
ber 20, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
the art department. J.D. is supported by a post-doctoral
fellowship (PC001528) from the Department of Defense
Prostate Cancer Research Program (PCRP). This work was
supported by a grant from the NIH (P01-CA13106) to G.J.H.
REFERENCES
1. Zheng,Y., Jung,M.K. and Oakley,B.R. (1991) g-Tubulin is present in
Drosophila melanogaster and Homo sapiens and is associated with the
centrosome. Cell, 65, 817±823.
2. Carroll,P.E., Okuda,M., Horn,H.F., Biddinger,P., Stambrook,P.J.,
Gleich,L.L., Li,Y.,Q., Tarapore,P. and Fukasawa,K. (1999) Centrosome
hyperampli®cation in human cancer: chromosome instability induced by
p53 mutation and/or Mdm2 overexpression. Oncogene, 18, 1935±1944.
3. Hsu,L.C. and White,R.L. (1998) BRAC1 is associated with the
centrosome during mitosis. Proc. Natl Acad. Sci. USA, 95, 12983±12988.
4. Matsumoto,Y., Hayashi,K. and Nishida,E. (1999) Cyclin dependent
kinase 2 (CDK2) is required for centrosome duplication in mammalian
cells. Curr. Biol., 9, 429±432.
5. Lange,B.M. (2002) Integration of the centrosome in cell cycle control,
stress response and signal transduction pathways. Curr. Opin. Cell Biol.,
14, 35±43.
6. Bornens,M. (2002) Centrosome composition and microtubule anchoring
mechanisms. Curr. Opin. Cell Biol., 14, 25±34.
7. Rieder,C.L., Faruki,S. and Khodjakov,A. (2001) The centrosome in
vertebrates: more than a microtubule-organizing center. Trends Cell
Biol., 11, 413±419.
8. Hinchcliffe,E.H. and Sluder,G. (2001) Centrosome duplication: three
kinases come up a winner! Curr. Biol., 11, R698±R701.
9. Doxsey,S. (2001) Re-evaluating centrosome function. Nature Rev. Mol.
Cell Biol., 2, 688±698.
10. Stearns,T. (2001) Centrosome duplication. A centriolar pas de deux. Cell,
105, 417±420.
11. Hinchcliffe,E.H., Miller,F.J., Cham,M., Khodjakov,A. and Sluder,G.
(2001) Requirement of a centrosomal activity for cell cycle progression
through G1 into S phase. Science, 291, 1547±1550.
Figure 5. (Previous two pages and above) The centrosome localization of STK15 and NM23-H1 is not microtubule dependent. (A) IMR90 cells grown on
coverslips were treated with or without nocodazole and ®xed for immuno¯uorescence. The centrosome was visualized by staining with anti-centrin2 and
anti-g-tubulin antibodies. As predicted, the signal representing centrosome-associated g-tubulin becomes signi®cantly weakened, especially in mitotic cells
(prometaphase cells here), upon nocodazole treatment (labeled w/ noc on the left), as compared to that seen in cells without nocodazole (labeled w/o noc on
the left). (B) STK15 and (C) NM23-H1 still localize to centrosome in nocodazole-treated cells throughout the cell cycle. IMR90 cells treated with or without
nocodazole (w/o noc) were ®xed and triple labeled for b-tubulin (FITC), STK15/NM23-H1 (Cy5), centrin2 (Texas red) and DNA (DAPI). The nocodazole
treatment totally dissipates the microtubule spindles so the cells with nocodazole fail to show the characteristic b-tubulin staining pattern (the b-tubulin
columns). Cell cycle stages are indicated on the left.
Nucleic Acids Research, 2002, Vol. 30, No. 24 5473
 at Cold Spring H
arbor Laboratory on D
ecem
ber 20, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
12. Khodjakov,A. and Rieder,C.L. (2001) Centrosomes enhance the ®delity
of cytokinesis in vertebrates and are required for cell cycle progression.
J. Cell Biol., 153, 237±242.
13. Piel,M., Nordberg,J., Euteneuer,U. and Bornens,M. (2001) Centrosome-
dependent exit of cytokinesis in animal cells. Science, 291, 1550±1553.
14. Salisbury,J.L. (2001) The contribution of epigenetic changes to abnormal
centrosomes and genomic instability in breast cancer. J. Mammary Gland
Biol. Neoplasia, 6, 203±212.
15. Pihan,G.A., Purohit,A., Wallace,J., Knecht,H., Woda,B., Quesenberry,P.
and Doxsey,S.J. (1998) Centrosome defects and genetic instability in
malignant tumors. Cancer Res., 58, 3974±3985.
16. Weber,R.G., Bridger,J.M., Benner,A., Weisenberger,D., Ehemann,V.,
Reifenberger,G. and Lichter,P. (1998) Centrosome ampli®cation as a
possible mechanism for numerical chromosome aberrations in cerebral
primitive neuroectodermal tumors with TP53 mutations. Cytogenet. Cell
Genet., 83, 266±269.
17. Gradimi,B.M., Sackett,D.L., Di®lippantonio,M.J., Schrock,E.,
Neumann,T., Jauho,A., Auer,G. and Reid,T. (2000) Centrosome
ampli®cation and instability occurs exclusively in aneuploidy, but not in
diploid colorectal cancer cell lines, and correlates with numerical
chromosomal aberrations. Genes Chromosomes Cancer, 27, 183±190.
18. Marx,J. (2001) Do centrosome abnormalities lead to cancer? Science,
292, 426±427.
19. Saavedra,H.I., Fukasawa,K., Conn,C.W. and Stambrook,P.J. (1999)
MAPK mediate ras-induced chromosome instability. J. Biol. Chem., 274,
38083±38090.
20. Tutt,A., Gabriel,A., Bertwistle,D., Connor,F., Paterson,H., Peacock,J.,
Ross,G. and Ashworth,A. (1999) Absence of BRCA2 causes genome
instability by chromosome breakage and loss associated with centrosome
ampli®cation. Curr. Biol., 9, 1107±1110.
21. Fukasawa,K., Choi,T., Kuriyama,R., Rulong,S. and Vande Woude,G.F.
(1996) Abnormal centrosome ampli®cation in the absence of p53.
Science, 271, 1744±1747.
22. Hollander,M.C., Sheikh,M.S., Bulavin,D.V., Lundgren,K.,
Augeri-Henmueller,L., Shehee,R., Molanaro,T.A., Kim,K.T., Tolosa,E.,
Ashwell,J.D. et al. (1999). Genomic instability in gadd45a-de®cient
mice. Nature Genet., 23, 176±184.
23. Meraldi,P., Lukas,J., Fry,A.M., Bartek,J. and Nigg,E.A. (1999)
Centrosome duplication in mammalian somatic cells required E2F and
Cdk2-Cyclin A. Nature Cell Biol., 1, 88±93.
24. Glover,D.M., Leibowitz,M.H., McLean,D.A. and Parry,H. (1995)
Mutations in aurora prevent centrosome separation leading to the
formation of monopolar spindles. Cell, 81, 95±105.
25. Bischoff,J.R., Anderson,L., Zhu,Y., Mossie,K., Ng,L., Souza,B.,
Schryver,B., Flanagan,P., Chairvoyant,F., Ginther,C. et al. (1998). A
homologue of Drosophila aurora kinase is oncogenic and ampli®ed in
human colorectal cancers. EMBO J., 17, 3052±3065.
26. Sen,S., Zhou,H. and White,R.A. (1997) A putative serine/threonine
kinase encoding gene BTAK on chromosome 20q13 is ampli®ed and
over expressed in human breast cancer cell lines. Oncogene, 14,
2195±2200.
27. Zhou,H., Kuang,J., Zhong,L., Kuo,W., Grey,J., Sahin,A., Brinkley,B. and
Sen,S. (1998) Tumor ampli®ed kinase STK15/BTAK induces centrosome
ampli®cation, aneuploidy and transformation. Nature Genet., 20,
189±193.
28. Tanaka,T., Kimura,M., Matsunaga,K., Fukada,D., Mori,H. and Okano,Y.
(1999) Centrosomal kinase AIK1 is overexpressed in invasive ductal
carcinoma of the breast. Cancer Res., 59, 2041±2044.
29. Miyoshi,Y., Iwao,K., Egawa,C. and Noguchi,S. (2001) Association of
centrosomal kinase STK15/BTAK mRNA expression with chromosomal
instability in human breast cancers. Int. J. Cancer, 92, 370±373.
30. Shin,S.O., Lee,K.H., Kim,J.H., Baek,S.H., Park,J.W., Gabrielson,E.W.
and Kwon,T.K. (2000) Alternative splicing in 5¢-untranslational region of
STK-15 gene, encoding centrosome associated kinase, in breast cancer
cell lines. Exp. Mol. Med., 32, 193±196.
31. Farruggio,D.C., Townsley,F.M. and Ruderman,J.V. (1999) Cdc20
associates with the kinase aurora2/Aik. Proc. Natl Acad. Sci. USA, 96,
7306±7311.
32. Honda,K., Mihara,H., Kato,Y., Yamaguchi,A., Tanaka,H., Yasuda,H.,
Furukawa,K. and Urano,T. (2000) Degradation of human Aurora2
protein kinase by the anaphase-promoting complex-ubiquitin-proteasome
pathway. Oncogene, 19, 2812±2819.
33. Walter,A.O., Seghezzi,W., Korver,W., Sheung,J. and Lees,E. (2000) The
mitotic serine/threonine kinase Aurora2/AIK is regulated by
phosphorylation and degradation. Oncogene, 19, 4906±4916.
34. Katayama,H., Zhou,H., Li,Q., Tatsuka,M. and Sen,S. (2001) Interaction
and feedback regulation between STK15/BTAK/Aurora-A kinase and
protein phosphatase 1 through mitotic cell division cycle. J. Biol. Chem.,
276, 46219±46224.
35. Hannak,E., Kirkham,M., Hyman,A.A. and Oegema,K. (2001) Aurora-1
kinase is required for centrosome maturation in Caenorhabditis elegans.
J. Cell Biol., 155, 1109±1115.
36. Steeg,P.S., Bevilacqua,G., Kopper,L., Thorgeirsson,U.P., Talmadge,J.E.,
Liotta,L.A. and Sobel,M.E. (1988) Evidence for a novel gene associated
with low tumor metastatic potential. J. Natl Cancer Inst., 80, 200±204.
37. Leone,A., Flatow,U., VanHoutte,K. and Steeg,P.S. (1993). Transfection
of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell
line: effects on tumor metastatic potential, colonization and enzymatic
activity. Oncogene, 8, 2325±2333.
38. Parhar,R.S., Shi,Y., Zou,M., Farid,N.R., Ernst,P. and Al-Sedairy,S.
(1995) Effects of cytokine-mediated modulation of nm23 expression on
the invasion and metastatic behavior of B16F10 melanoma cells. Int. J.
Cancer, 60, 204±210.
39. Baba,H., Urano,T. and Okada,K. (1995) Two isotypes of murine nm23/
nucleoside diphosphate kinase, nm23-M1 and nm23-M2, are involved in
metastatic suppression of a murine melanoma line. Cancer Res., 55,
1977±1981.
40. Freije,J.M.P., MacDonald,N.J. and Steeg,P.S. (1998) Nm23 and tumor
metastasis: basic and translational advances. Biochem. Soc. Symp., 63,
261±271.
41. Lacombe,M., Milon,L., Munier,A. and Lambeth,D.O. (2000) The human
Nm23/nucleoside diphosphate kinases. J. Bioenerg. Biomembr., 32,
247±258.
42. Parks,R.E.,Jr and Agarwal,R.P. (1973) Nucleoside diphosphokinases. In
Boyer,P.D. (ed.), The Enzymes, 3rd Edn. Academic Press, New York,
Vol. 8, pp. 307±333.
43. Wagner,P. and Vu,N.D. (1995) Phosphorylation of ATP-citrate lyase by
nucleoside diphosphate kinase. J. Biol. Chem., 270, 21758±21764.
44. Engel,M., Veron,M., Theisinger,B., Lacombe,M.L., Seib,T., Dooley,S.
and Welter,C. (1995) A novel serine/threonine-speci®c protein
phosphotransferase activity on Nm23/nucleoside-diphosphate kinase.
Eur. J. Biochem., 234, 200±207.
45. Wagner,P.D., Steeg,P.S. and Vu,N.D. (1997) Two-component kinase-
like activity of nm23 correlates with its motility-suppressing activity.
Proc. Natl Acad. Sci. USA, 94, 9000±9005.
46. MacDonald,N.J., De la Rosa,A., Bebedict,M.A., Frejie,J.M.P.,
Krutsch,H. and Steeg,P.S. (1993) A serine phosphorylation of Nm23, and
not its nucleoside diphosphate kinase activity, correlates with
suppression of tumor metastatic potential. J. Biol. Chem., 268,
25780±25789.
47. Hemmerich,S. and Pecht,I. (1992) A cromoglycate binding protein from
rat mast cells of a leukemia line is a nucleoside diphosphate kinase.
Biochemistry, 31, 4580±4587.
48. Lombardi,D., Sacchi,A., D'Angostino,G. and Tibursi,G. (1995) The
association of the Nm23-M1 protein and b-tubulin correlates with cell
differentiation. Exp. Cell Res., 217, 267±271.
49. Biggs,J., Hersperger,E., Steeg,P.S., Liotta,L.A. and Shearn,A. (1990) A
Drosophila gene that is homologous to a mammalian gene associated
with tumor metastasis codes for a nucleoside diphosphate kinase. Cell,
63, 933±940.
50. Roymans,D., Vissenberg,K., De Jongle,C., Willems,R., Engler,G.,
Kiruma,N., Brobben,B., Claes,P., Verbelen,J.-P., Van Broeckhoven,C.
et al. (2001) Identi®cation of the tumor metastasis suppressor Nm23-H1/
Nm23-R1 as a constituent of the centrosome. Exp. Cell Res., 262,
145±153.
51. Hannon,G.J., Demetrick,D. and Beach,D. (1993) Isolation of the Rb-
related p130 through its interaction with CDK2 and cyclins. Genes Dev.,
7, 2378±2391.
52. Wang,J., Xie,L.Y., Allan,S., Beach,D. and Hannon,G.J. (1998) Myc
activates telomerase. Genes Dev., 12, 1769±1774.
53. Guan,K.L. and Dixon,J.E. (1991) Eukaryotic proteins expressed in
E.coli: an improved thrombin cleavage and puri®cation procedure of
fusion proteins with glutathione S-transferase. Anal. Biochem., 192,
262±267.
54. Du,J., Nasir,I., Benton,B.K., Kladde,M.P. and Laurent,B.C. (1998)
Sth1p, a Saccharomyces cerevisiae Snf2p/Swi2p homolog, is an essential
5474 Nucleic Acids Research, 2002, Vol. 30, No. 24
 at Cold Spring H
arbor Laboratory on D
ecem
ber 20, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
ATPase in RSC and differs from Snf/Swi in its interactions with histones
and chromatin-associated proteins. Genetics, 150, 987±1005.
55. Xiong,Y., Zhang,H. and Beach,D. (1993) Subunit rearrangement of the
cyclin-dependent kinases is associated with cellular transformation.
Genes Dev., 7, 1572±1583.
56. Vorobjev,I.A., Uzbekov,R.E., Komarova,Yu.A. and Alieva,I.B. (2000)
Gamma-tubulin distribution in interphase and mitotic cells upon
stabilization and depolymerization of microtubules. Membr. Cell Biol.,
14, 219±235.
57. Giet,R. and Prigent,C. (2001) The non-catalytic domain of the Xenopus
laevis aurora-A kinase localizes the protein to the centrosome. J. Cell
Sci., 114, 2095±2104.
58. Biggs,J., Hersperger,E., Steeg,P.S., Ioitta,L.A. and Shearn,A. (1990) A
Drosophila gene that is homologous to a mammalian gene associated
with tumor metastasis codes for a nucleoside diphosphate kinase. Cell,
63, 933±940.
Nucleic Acids Research, 2002, Vol. 30, No. 24 5475
 at Cold Spring H
arbor Laboratory on D
ecem
ber 20, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
